Supplementary Figure S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown